Instrument Inactif

Communiqués OvaScience Inc OTC Bulletin Board

Actions

US69014Q1013

Recherche biotechnologique et médicale

Cours en clôture OTC Bulletin Board Autres places de cotation
- ^USD	-

10/05/23	Millendo Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2023	CI
22/06/21	Les investisseurs de Millendo et Tempest Therapeutics approuvent les propositions de fusion	MT

Communiqués

23/07/21	TEMPEST THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
16/07/21	Tempest Therapeutics : BUSINESS (Form 8-K)	PU
16/07/21	TEMPEST THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
12/07/21	Tempest Therapeutics : to Participate in William Blair 2021 Biotech Focus Conference	AQ
12/07/21	TEMPEST THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)	AQ
09/07/21	Tempest Therapeutics : to Participate in William Blair 2021 Biotech Focus Conference	AQ
07/07/21	TEMPEST THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
02/07/21	Millendo Therapeutics : Amendment to Current Report (SEC Filing - 8-K/A)	PU
01/07/21	Tempest Therapeutics : MILLENDO THERAPEUTICS, INC. Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits (form 8-K/A)	AQ
28/06/21	Millendo Therapeutics : Tempest Closes Merger with Millendo and Completes PIPE Financing (Form 8-K)	PU
23/06/21	Millendo Therapeutics : Tempest and Millendo Announce Stockholder Approval of Merger (Form 8-K)	PU
23/06/21	MILLENDO THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
11/06/21	MILLENDO THERAPEUTICS, INC. : Other Events (form 8-K)	AQ
13/05/21	MILLENDO THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
08/04/21	MILLENDO INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Millendo Therapeutics, Inc. - MLND	BU
29/03/21	MILLENDO THERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ
29/03/21	MILLENDO THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
29/03/21	Millendo Therapeutics : Tempest and Millendo Announce Proposed Merger Agreement	BU
28/01/21	MILLENDO THERAPEUTICS, INC. : Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
05/01/21	MILLENDO THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
05/01/21	Millendo Therapeutics : Provides Pipeline and Business Update	BU
09/11/20	Millendo Therapeutics : Reports Third Quarter 2020 Operating and Financial Results	BU
09/11/20	MILLENDO THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
25/09/20	Millendo Therapeutics : Announces Initiation of First-in-Human Clinical Trial of MLE-301, a Selective NK3R Antagonist	AQ
24/09/20	MILLENDO THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ